ICON provides the experience and expertise across multiple classes of infection to address the critical issues of infectious disease research. In the past five years, ICON has conducted approximately 216 clinical anti-infective studies, assessing over 73,215 patients at 5,244 sites worldwide.

Our clinical trial experience includes but is not limited to the following anti-infective indications:

In the past five years, ICON has conducted approximately 36 clinical vaccine trials, assessing over 42,745 patients at more than 1,050 sites worldwide. Our extensive vaccine trial experience spans across multiple therapeutic indications and all age groups including:

ICON’s Anti-Infective/Anti-Viral/Vaccine TAG comprises of in-house therapeutic experts who can provide the specialised knowledge required to address the unique challenges of developing drugs to combat infectious diseases. They provide insight into:

• Diagnoses and treatment of infectious diseases
• Currently available anti-infective drugs; their mode of action, efficacy and safety
• Specific risks of anti-infective drug development and how to manage them
• Specialised knowledge of clinical trial methodology and efficacy assessment methods
• Relationships with key opinion leaders around the globe
• Access to a well established global network of investigators in infectious diseases, vaccines and public health
• Market intelligence for anti-infective therapies

Our global investigator database includes over 595 anti-infective and vaccine investigative sites across more than 35 countries. We have worked with a wealth of specialty investigators in the areas of Prophylactic Vaccines, Ancillary Infectious Topics, Bacterial Infectious Disorders, Chlamydia Infections, Ectoparasitic Disorders, Fungal Infections, Helminthic Disorders, Mycobacterial, Mycoplasmal, Protozoa, Rickettsial and Viral Infectious Disorders.